Drugs / D-serine
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07079930 | Dec 2025 → Nov 2026 expected | — | Hadassah Medical Organization | Recruiting | No outcome recorded |
| Phase 1/23 trials · 1 met primary | ||||||
| Phase 1/2 | NCT05046353 | Dec 2022 → Apr 2027 | schizoaffective disorder, schizophrenia | New York State Psychiatric Institute | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03711500 | Mar 2019 → Apr 2021 | schizoaffective disorder, schizophrenia | New York State Psychiatric Institute | Completed | Met primary |
| Phase 1/2 | NCT00215917 | — | schizophrenia | Herzog Hospital | Unknown | No outcome recorded |
| Phase 29 trials · 3 met primary · 1 missed | ||||||
| Phase 2 | NCT02156908 | Aug 2014 → Dec 2015 | schizophrenia | Nathan Kline Institute for Psychiatric Research | Completed | No outcome recorded |
| Phase 2 | NCT01474395 | Mar 2012 → Jun 2013 | schizoaffective disorder, schizophrenia | Nathan Kline Institute for Psychiatric Research | Unknown | No outcome recorded |
| Phase 2 | NCT00817336 | Jun 2009 → Jul 2011 | schizoaffective disorder, schizophrenia | Nathan Kline Institute for Psychiatric Research | Completed | Met primary |
| Phase 2 | NCT00826202 | Mar 2009 → Nov 2012 | schizophrenia | Nathan Kline Institute for Psychiatric Research | Completed | Met primary |
| Phase 2 | NCT00816894 | Jan 2009 → Feb 2013 | schizophrenia | Herzog Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00322023 | Mar 2006 → Jan 2009 | schizophrenia | Nathan Kline Institute for Psychiatric Research | Completed | Met primary |
| Phase 2 | NCT00491569 | Jan 2005 → Dec 2006 | schizophrenia | China Medical University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00138775 | Oct 2004 → Oct 2007 | schizoaffective disorder, schizophrenia | Sheba Medical Center | Unknown | Missed primary |
| Phase 2 | NCT00215878 | Aug 2003 → May 2008 | post-traumatic stress disorder | Herzog Hospital | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07263022 | Jul 2026 → Apr 2030 expected | bipolar disorder, major depressive disorder, schizoaffective disorder, schizophrenia +1 | University of Minnesota | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT00237848 | Feb 2005 → ? | schizoaffective disorder, schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT00237809 | Sep 2002 → Dec 2010 | schizoaffective disorder, schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01018056 | Nov 2009 → Sep 2013 | Tourette syndrome | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT00215904 | Aug 2003 → May 2008 | Parkinson disease | Herzog Hospital | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT06876129 Comparator | Apr 2025 → Dec 2026 expected | depressive disorder | Mclean Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT03778320 Comparator | Dec 2018 | — | Concert Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01715051 Comparator | Feb 2014 → Sep 2019 | cocaine dependence | Theresa Winhusen | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT01459029 Comparator | Nov 2011 → Oct 2013 | schizophrenia | Hadassah Medical Organization | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | d-serine | “Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the...” PMID 36958998 ↗ Jan 202323“We recently demonstrated significant improvement in auditory mismatch negativity (MMN) with once-weekly treatment with d-serine, a naturally occurring NMDAR glycine-site agonist.” PMID 28318835 ↗ Mar 2017 |
| Known as | DSR | “We will be investigating the effect of D-serine, (DSR), a selective and potent NMDAR agonist, as monotherapy for treatment resistant schizophrenics.” NCT00215917 ↗3“D-serine (DSR), is a full agonist, and is therefore more ideal for enhancing NMDA function and cognitive remediation.” NCT01474395 ↗ “d-serine (DSR) is an endogenous full agonist at the NMDAR-associated glycine modulatory site.” PMID 19366490 ↗ Apr 2009 “D-serine (DSR) allosterically modulates in-vivo NMDAR-mediated neurotransmission.” PMID 21733283 ↗ Jul 2011 |
| Action | Activate | “The proposed experiment will evaluate the effects of the NMDA receptor full agonist D-serine” NCT00215904 ↗ |
| Route | Oral | “they will drink a D-serine powder mixed with water twice daily.” NCT00322023 ↗ |